Despite Imfinzi fail in lung cancer trial, AZ 'encouraged' by one result: exec

AstraZeneca's oncology efforts have yielded some major wins over the last year, but Monday the drugmaker revealed a lung cancer setback for its blockbuster Imfinzi. In the phase 3 PEARL study, Imfinzi failed to meet its primary endpoint of extending overall survival in certain metastatic lung cancer patients. Specifically, investigators tested the immuno-oncology drug against chemotherapy in patients with stage IV non-small cell lung cancer with high levels (25% or more) of PD-L1, or those with a low risk of early mortality.